ASLAN Pharmaceuticals Limited
ASLN · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $17 | $50 | $146 | $141 |
| - Cash | $21 | $57 | $90 | $14 |
| + Debt | $27 | $38 | $31 | $19 |
| Enterprise Value | $23 | $31 | $87 | $146 |
| Revenue | $12 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $12 | -$0 | -$0 | -$0 |
| % Margin | 97.1% | – | – | – |
| EBITDA | -$39 | -$47 | -$29 | -$15 |
| % Margin | -328.4% | – | – | – |
| Net Income | -$44 | -$51 | -$35 | -$18 |
| % Margin | -368.5% | – | – | – |
| EPS Diluted | -10.76 | -14.72 | -10.64 | -9.32 |
| % Growth | 26.9% | -38.3% | -14.2% | – |
| Operating Cash Flow | -$46 | -$38 | -$34 | -$15 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$46 | -$38 | -$34 | -$15 |